Pharmaceutical Industry Fellowship Program

In Partnership with

Genentech
A Member of the Roche Group

Rutgers Institute for Pharmaceutical Industry Fellowships
Dear Prospective Fellow,

On behalf of the Roche Group and the Ernest Mario School of Pharmacy at Rutgers University, we thank you for your interest in a Fellowship at Genentech, a member of the Roche Group. A global pioneer in healthcare since 1896, Roche is a world leader in biotechnology and in vitro diagnostics, creating and delivering innovative medicines and diagnostic tests for patients worldwide. We are passionate and rigorous about our science. For more than 30 years, Roche has also played a major role in fostering the professional growth of pharmacists in pharmaceutical research, development, and commercialization. We offer motivated PharmD graduates, who share our purpose to improve the lives of patients, exciting opportunities to develop their skills and pursue their interests at Genentech’s US Headquarters for Roche Pharmaceutical Operations in South San Francisco, California, where the biotechnology industry began and continues to thrive.

We aim to cultivate one of the best educational environments for Pharm.D. graduates through our commitment to quality and excellence. Fellows have the opportunity to develop or enhance their knowledge and skills while experiencing a corporate culture that encourages diversity of thought, style, skill, and perspective as well as a dynamic environment of international colleagues. While the Fellowship is structured, it is still flexible enough to allow participants to engage in a wide array of unique opportunities and obtain a solid experience in the healthcare industry. We look forward to meeting you and discussing how this program can serve as your pathway to an exciting career in helping to improve patients’ lives.

Patrick Schleck, PharmD, MBA
Pharma Partnering Global Head, Immunology and Infectious Disease
Genentech RPIF Program Director

Table of Contents

Leadership Team 4
About Roche & Genentech 5
Our Fellowship Components 6
Overview of Fellowship Positions 7
Fellowship Position Descriptions 8
Rutgers Program
  Program History 17
  Application Process & Requirements 18
Our History

Roche was founded in 1896 in Basel, Switzerland by Fritz Hoffmann-La Roche at a time when the industrial revolution was changing the face of Europe. He was among the first to recognize that the industrial manufacture of medicines would be a major advance in the fight against disease.

Genentech was founded in 1976 as a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Genentech’s transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis.

In 2009, Genentech became a member of the Roche Group—now the largest biotechnology company in the world. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States.

In 2009, Genentech became a member of the Roche Group—now the largest biotechnology company in the world. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States.

Who We Are

We have always worked to drive scientific discovery and redefine what is possible to improve patients’ lives. We are working on understanding how diseases differ down to the molecular level to develop new tests and medicines that prevent, diagnose, and treat diseases that matter and bring them to the patients who need them. With our combined strengths in diagnostics and pharmaceuticals, our personalized healthcare strategy aims to fit the right treatment to the right patient.

As the world’s largest biotech company, we develop breakthrough medicines, improving the standard-of-care across oncology, immunology, infectious diseases, ophthalmology and neuroscience. This track record allows us to build lasting and meaningful partnerships across the world with research academia and public healthcare institutions. The founding families continue to hold the majority stake in the company. This stability allows for a tradition of sustainable thinking, so we can learn from setbacks and focus on lasting value for patients and society. We remain dedicated to the highest standards of quality, safety, and integrity. Our legacy is based on respect for the individual, the communities and the world we live in.

Our Purpose

We believe it is urgent to deliver medical solutions right now—even as we develop innovations for the future. We are passionate about transforming patients’ lives. We are courageous in both decision and action. And we believe that good business means a better world. That is why we come to work each day.

We commit ourselves to scientific rigor, unassailable ethics, and access to medical innovations for all. We do this today to build a better tomorrow. We are proud of who we are, what we do, and how we do it. We are many, working as one across functions, across companies, and across the world.
Roche Launched 18 New Molecules Since 2011

- Oncology, Infectious Disease, Immunology, Ophthalmology, Neuroscience, Rare Diseases
- Medicines in the WHO Model List for Essential Medicines
- FDA-approved medicines for serious & life-threatening diseases
- Investigational medicines in development
- Clinical trials worldwide
- Clinical trials in the U.S.

Investing in Innovation

Roche is a leading healthcare company dedicated to innovation in a sustainable way.

Cultivating a Great Workplace

Roche has been recognized with various awards and accolades for its innovative work environment and commitment to excellence.

- 15 Years on the List
- 14 Years on the List
- 11 Years on the List

The Roche Group

- $11 Billion in R&D
- 6 Areas of Focus
- 32 Areas of Focus
- 40+ Medicines in the WHO Model List for Essential Medicines
- 40+ FDA-approved medicines for serious & life-threatening diseases
- 130+ Investigational medicines in development
- 1150+ Clinical trials worldwide
- 570+ Clinical trials in the U.S.

The Palace of Fine Arts, SF
Our Fellowship Components

At Genentech, fellows are valuable assets within their chosen functional area. Rooted in our commitment to pursuing groundbreaking science and addressing unmet needs, this robust program allows for a fellow’s further development and fine tuning of skills.

Mentorship Program

The mentorship program pairs fellows with experienced mentors currently on their study team either within Genentech or Roche. This provides the fellow with additional support in their day-to-day activities outside of their co-fellows & preceptors.

The mentorship program aims to give fellows continued career guidance and professional development through the collaborative efforts of Genentech and Roche.

Networking Opportunities

Pharmacists Network
Network with other PharmDs at Genentech

Genentech Rotational Network
Network with professionals completing rotational programs at Genentech

Training & Development Partnership
Provides training across functional roles and therapeutic areas for commercial colleagues and provides soft skills & behavioral trainings for all Genentech employees

Fellowship Alumni Network

Roche was one of the 1st companies to partner with RPIF

There are 50+ RPIF Alumni currently employed at Roche Genentech

Many preceptors & Fellowship Leadership Team members are RPIF alumni & are actively engaged

Rotation Opportunity

At Genentech, we prioritize the development of each fellow. Our fellowships are structured to maximize exposure to various roles within industry, specifically within the fellow’s chosen functional area. Certain fellowships offer a rotational opportunity during the fellow’s second year in order to gain hands-on experience in an additional functional area of interest.

Locations that fellows have rotated in the past:
- Roche Innovation Center New York
- Hoffman – La Roche, Inc Washington D.C.
- Roche Diagnostics Indianapolis
- Genentech San Francisco
Overview of Fellowship Positions
Recruiting for 2021–2023

Clinical Operations: 3
Clinical Science Late Stage Development: 3
Product Development: 1
Clinical Safety: 2
Regulatory Affairs Strategy: 2
US Medical Affairs / Medical Communication: 2
US Medical Affairs / Medical Science Liaisons: 2
US Medical Affairs / Medical Science Directors
Personalized Health Care
Our Clinical Operations organizations are dedicated to the planning and management of clinical trials. We drive success in bringing life-changing medicines to patients by efficiently delivering high-quality clinical programs evaluating the safety and efficacy of approved and developmental molecules.

Working cross-functionally, Fellows will develop and execute strategies to deliver on operational aspects of studies through all phases of study management. At Roche/Genentech, Clinical Operations propels trials to run faster and smarter, from streamlining processes and improving the patient experience to adapting to the rapidly evolving clinical trial landscape.

Within Clinical Operations, Genentech offers one fellowship position in each of the following areas:

- Global Oncology
- Global Immunology, Infectious Disease, Ophthalmology, and Neuroscience (I2ON)
- US Medical Affairs, Evidence Generation

Fellow responsibilities may include:

- Providing operational input to the development of study deliverables, such as feasibility questionnaires and patient recruitment and retention strategies
- Organizing investigator meetings, monitor trainings and Contract Research Organization (CRO) kick-off meetings
- Developing and managing operational plans related to site monitoring, risk mitigation, trial budgets, site selection, study timelines, quality and clinical supplies
- Establishing and driving timelines for study milestones and ensuring accurate tracking and reporting of study metrics
- Providing direction and leadership to the operations team, while collaborating closely cross-functionally

During the second year of the Fellowship, Clinical Operations Fellows have the opportunity to participate in a broad range of rotations at Genentech or within the Roche Group

Preceptors

Operations Program Leader, Program Development Global Clinical Operations Oncology

Eva Cybulski, PharmD
Midwestern University

Vivian Truong, PharmD
California Northstate University

Monica Eason
Operations Program Leader, Program Development Global Clinical Operations I2ON

Joseph Hubbard, PharmD, RPh
University of Michigan

Neala Rafijah, MS, PharmD
University of California, San Francisco

Brianna Mengini, PharmD
University of the Sciences

Recruiting Positions in:

<table>
<thead>
<tr>
<th>Position</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Global Oncology</td>
<td>1</td>
</tr>
<tr>
<td>Global I2ON</td>
<td>1</td>
</tr>
<tr>
<td>USMA</td>
<td>1</td>
</tr>
</tbody>
</table>

Preceptors 2019-2021 Fellows

Jenee Pan, PharmD
Operations Program Leader, Product Development Global Clinical Operations Oncology

Eva Cybulski, PharmD
Midwestern University

Vivian Truong, PharmD
California Northstate University

Monica Eason
Operations Program Leader, Program Development Global Clinical Operations I2ON

Joseph Hubbard, PharmD, RPh
University of Michigan

Neala Rafijah, MS, PharmD
University of California, San Francisco

Brianna Mengini, PharmD
University of the Sciences

2020-2022 Fellows

Salah El-Saheb, BSc, PharmD
Clinical Operations Leader
US Medical Affairs

Jenee Pan, PharmD
Operations Program Leader, Product Development Global Clinical Operations Oncology

Eva Cybulski, PharmD
Midwestern University

Vivian Truong, PharmD
California Northstate University

Monica Eason
Operations Program Leader, Program Development Global Clinical Operations I2ON

Joseph Hubbard, PharmD, RPh
University of Michigan

Neala Rafijah, MS, PharmD
University of California, San Francisco

Brianna Mengini, PharmD
University of the Sciences
The development of effective and safe medications for patients is our primary focus at Genentech. The mission of Product Development Clinical Science (PDC) is to develop and execute innovative and robust development programs to deliver well-characterized and differentiated medicines to patients with unmet medical need. PDC includes 3 therapeutic areas: Oncology (PDO), Neuroscience (PDN), and Immunology, Infectious Diseases, and Ophthalmology (I2O).

The Fellows accepted into our program will have a contributing role in clinical trial design and execution by assisting in writing protocols, informed consents, data review, scientific publications and presentations, as well as providing ongoing scientific guidance throughout study conduct. The Fellows may also be involved in the analysis of molecule-wide safety signals, analysis of study-related data, and contribute to authorship of regulatory documents.

PDC specializes in late stage clinical development, conducting primarily Phase II/III clinical trials with an aim to further characterize the clinical efficacy and safety profile of a molecule before the registration/approval process. During the fellowship, the Fellow will receive professional experiences in the following capacities:

- Develop a deep understanding of the molecules in the late-stage pipeline
- Ascertain the risk/benefit profile of tested molecules and understand the criteria for moving further in development
- Author key scientific documentation for clinical studies
- Assist in ongoing clinical development plans by working closely with Clinical Scientists and Medical Directors on strategic initiatives
- Enhance scientific communication skills through presentations, medical congresses and professional meetings
**PRODUCT DEVELOPMENT**

**CLINICAL SAFETY**

**OVERVIEW**

The Product Development Clinical Safety (PDS) department is responsible for the characterization of the safety profile of Roche's products at all stages of development. Safety scientists work collaboratively across the Roche organization to bring strategic, proactive, and scientific value to our pharmacovigilance and risk management strategies. This work ensures that Roche products are effective therapies with a positive benefit-risk ratio for our patients.

The Fellow will develop skills in pharmacovigilance practices through active involvement in clinical trial and post marketing safety surveillance, assessment of safety signals, and risk management activities.

**ACTIVITIES**

Evaluation and analysis of adverse events in clinical trials and post marketing signal detection and signal management

- Learning and understanding of global requirements for the reporting and surveillance of adverse events
- Maintenance and update of safety related information in US and global product labels, investigator brochures, informed consent forms
- Preparation of aggregate safety reports
- Risk management plan development and maintenance
- Gain experience in being able to use safety data analytics tools to manage signal detection or safety signal tracking
- Cross-functional interactions with other departments within Product Development

During the second year of the Fellowship, Clinical Safety Fellows have the opportunity to participate in a broad range of rotations at Genentech or within the Roche Group.
Regulatory Affairs - Strategy

Overview
Successful drug development within the pharmaceutical industry requires compliance with global regulations and collaboration with global health authorities. Regulatory professionals provide the interpretation of global regulations within the company to facilitate drug development that meets the needs of Health Authorities, patients, and prescribers. Regulatory professionals are also responsible for the design and implementation of regulatory strategies to optimally develop, license, and market products globally.

At Genentech, Regulatory Affairs - Strategy Fellows will receive individual guidance from regulatory professionals and obtain an understanding of the regulatory roles and responsibilities in the drug development process. Each Fellow will learn how to apply regulations and health authority guidance in the drug development process, develop regulatory strategies in collaboration with global project teams, and interact with Health Authorities.

Activities
The Fellow will acquire an understanding of the early and late stage drug development process across distinct therapeutic areas: Oncology, Immunology, Infectious Disease, Ophthalmology, and Neuroscience, through direct experience and/or exposure to:

- Investigational New Drug Application
- Biologic License Application
- Health Authority Interactions
- Post Marketing Activities
- Regulatory Records & Info
- Clinical Regulatory Documentation
- Chemistry, Manufacturing, & Controls
- Companion Diagnostics
- Clinical Trial Conduct
- Regulatory Strategy
- Labeling
- Regulatory Intelligence

During the second year of the Fellowship, Regulatory Affairs - Strategy Fellows have the opportunity to participate in a broad range of rotations at Genentech or within the Roche Group.
The Medical Affairs / Medical Communications Fellowship is a two-year program designed to expose the Fellow to a broad range of US Medical Affairs activities, with a focus on Medical Communication activities.

During the first year, the fellow will learn how to effectively communicate customer-focused clinical information on our pipeline and marketed products to patients, healthcare professionals, and managed care entities as well as engage with external customers involved in evidence-based healthcare decisions including managed care organizations, private and government health plans, PBMs, guideline bodies, and more. Additionally, the fellow will support the development of cutting-edge digital services and platforms to deliver exceptional customer experience.

The second year provides a unique opportunity to explore other departments through a few long-term rotations within Medical Affairs (Medical team, Clinical trials, MSL, HEOR) or outside of Medical Affairs (Digital Strategy, Marketing, Government Affairs). The focus of the second year is guided by the interests of the fellow and business needs.

The primary goals of the Fellowship are to provide the fellow with a thorough knowledge of Medical Affairs activities, and to build foundational scientific and professional skill sets required for a successful career within the pharmaceutical industry:

- Gain clinical proficiency and knowledge of key access strategies for a therapeutic area
- Evaluate medical literature and create accurate, fair-balanced medical content for external scientific engagement with customers within healthcare ecosystems
- Provide medical review of materials for both scientific exchange and promotional use
- Support pre-launch preparations for potential new molecular entities and label expansions
- Curate customer insights to identify strategic opportunities for medical teams
- Develop digital strategies to deliver exceptional customer experience
- Additional activities in second year based on rotations guided by the fellow's interests

During the second year of the Fellowship, USMA / Med Comm Fellows have the opportunity to participate in a broad range of rotations at Genentech or within the Roche Group.
OVERVIEW

US Medical Affairs / Medical Science Liaison

A network of clinical and scientific collaborators is responsible for developing and executing medical strategy for both marketed and pipeline molecules for the US affiliate. The network supports Medical Science Liaison (MSL) activities by serving as subject matter experts and ensuring strategic alignment across Medical Affairs.

The US Medical Affairs / MSL Fellowship is a two-year program based in South San Francisco, designed to expose the Fellow to a broad range of corporate and field-based US Medical Affairs activities within their assigned Medical Unit. The focus of the second year is determined by the mutual interests of the Fellow and the company.

ACTIVITIES

Medical Affairs Component:
The Fellowship will provide the Fellow with a thorough knowledge of US Medical Affairs core functions and develop foundational scientific and professional skill sets required for a successful career. The Fellow will have the opportunity to participate or lead:

• Tactic execution with the Medical Science Directors who support medical strategy
• Pre- and peri-approval preparations for new molecular entities
• Clinical insights with colleagues across various cross-functional departments
• Development of training and tools for the Field Medical Team

MSL Component:
Alongside the Medical Affairs experience, the Fellow will have the opportunity to participate in or lead:

• MSL strategy planning and execution with MSL leadership
• In-field scientific exchange through provision of provider education
• Execution of advisory boards and congress oral and poster presentations

Recruiting Positions in: Number:
USMA / MSL Respiratory 1
USMA / MSL Ophthalmology 1

Preceptors

Stephanie Hines, PharmD
Principal Medical Science Liaison
Respiratory

Karen Colbert, PhD
Senior Medical Science Liaison
Ophthalmology

Jessica Priest, PharmD
Senior Medical Science Liaison
Neuroscience

Catherine Sterk, PharmD
Field Lead West
Lung/GU/Dermatology, BioOncology

2019-2021 Fellow

Dakota Rosenfelt, PharmD, RPh
University of Missouri, Kansas City

2020-2022 Fellows

Bea Da Silva, PharmD
University of Colorado

Dmitri Aldershoff, PharmD, MBA, RPh
Albany College of Pharmacy and Health Sciences/Clarkson University

Non-Recruiting USMA/MSL Positions for 2021 - 2023

Solid tumors
Neuroscience
Hematology
US Medical Affairs / Medical Science Director

A network of clinical and scientific collaborators is responsible for developing and executing PHC goals for clinical trials and digital health for both marketed and pipeline molecules for the US affiliate. The network supports Medical Science Director (MSD) activities by serving as key experts and supporting tactical execution of our strategies.

The US Medical Affairs / MSD Fellowship is a two-year program based in South San Francisco, designed to expose the Fellow to a broad range of corporate US Medical Affairs activities within Personalized Health Care (PHC), BioOncology. The focus of the second year is determined by the mutual interests of the Fellow and the company.

Goals of PHC:
- Focus on patient experience
- Promote diversity & inclusion
- Transform oncology care

During the second year of the Fellowship, USMA / MSD PHC Fellows have the opportunity to participate in a broad range of rotations at Genentech or within the Roche Group.

Preceptors

Marianne Chacon, MD
USMA Digital Health Team Lead
PHC Oncology

Tania Szado, PhD
USMA PHC and Portfolio Team Lead
PHC Oncology

Young Kim, PharmD
Rutgers University

2020-2022 Fellow

This Fellowship will provide knowledge of US Medical Affairs core functions and develop scientific and professional skill sets required for a successful career. The Fellow will have opportunities to participate in or lead:

PHC in Evidence Generation:
- Tactic execution with Medical Science Directors who support medical strategy
- Site initiation activities and collaboration with Study Review Teams
- Protocol development and Study Management Team startup activities for prospective Next-Generation Sequencing clinical trials

PHC in Digital Health:
- Implementation of digital health strategies and digital tools to transform clinical care and patient outcomes/experiences
- Collaboration in data generation and dissemination of novel clinical trials including (but not limiting to) decentralized clinical trials, telemedicine, remote digital patient monitoring and digital biomarkers/endpoints
- Evidence-based complementary digital health interventions with stakeholders
PHARMA PARTNERING

OVERVIEW

Partnering strengthens Roche’s internal research, development, and commercial portfolio by building alliances with world-class leaders in the pharmaceutical and biotechnology industries. By mobilizing other functions at Roche and Genentech, Partnering maximizes the potential of these assets through creative deal terms and fostering a collaborative relationship with the partner.

45% of our R&D pipeline externally sourced

122 Partnerships managed in 2017 by Roche Partnering

Want

Defining our search

Find

Identifying partners

Get

Personalizing deals

Manage

Building relationships

Within Pharma Partnering, Business Development and Alliance Management work in harmony to pursue key collaborations that build on the Roche portfolio and strategically grow partnerships to further the Roche mission of “Doing Now What Patients Need Next.”

ACTIVITIES

• Be the “face of Roche/Genentech” liaising with CEO, alliance counterpart and senior leadership of partner companies.
• Strategic leadership of alliances which emerge from various deals including in-licensing, out-licensing, research collaborations, as well as leading the integration following merger and acquisition deals.
• Effective leadership of collaborations within Genentech Research, Roche Research, Development or Commercialization and those that are across different therapeutic areas.
• Lead and negotiate deals which arise from existing alliances. Allowing the opportunity to create and lead a cross-functional deal team, as well as lead diligence activities, term sheet and contractual negotiations.
• Establish and lead joint governance committee meetings to ensure appropriate decision making on partnered programs.
• Participate in out-partnering or divestment of commercial products in coordination with Roche global functions.

Preceptor

Beth Odeh-Brikert, PharmD
Head SSF Global Alliance and Asset Management Pharma Partnering

2020-2022 Fellow

Dena Badran, PharmD
St. Louis College of Pharmacy

During the second year of the Fellowship, Pharma Partnering Fellows have the opportunity to participate in a broad range of rotations at Genentech or within the Roche Group.
We look forward to meeting you!

Please stay safe during these challenging times.
All fellows gather at Rutgers once monthly as a group to participate in the Professional Development Day (PDD) Series, an important component of their training that complements the hands-on experience provided at the partner companies. The PDD’s are steered by a committee of fellows and are designed to enhance the fellows’ presentation skills, emotional intelligence, promote connectivity and a sense of community among fellows from different companies and disciplines, develop new skill sets under the guidance of external trainers, and provide general knowledge about various aspects of drug development and issues facing the pharmaceutical and biopharmaceutical industries.

The fellows learn from each other through individual and group presentations and debates on topics related to the pharmaceutical and biopharmaceutical industries. This dynamic forum provides an opportunity for open discussion and debate among fellows, Rutgers faculty, and company preceptors. In addition, outside experts provide training and professional development in a variety of areas (e.g., tools for corporate success; professional writing, presentations, meeting facilitation, negotiating, influencing, networking, and conflict resolution skills; giving and receiving feedback; and business and dining etiquette). Other PDD guest speakers include senior industry executives, patient advocacy groups, and successful RPIF Program alumni who share their insights and experiences.

Importantly, PDDs provide an excellent opportunity for fellows to interact with each other and develop lasting personal friendships and a strong professional network of fellows, faculty, alumni, and other industry executives.

In 1984, at Rutgers,
The State University of New Jersey, the Ernest Mario School of Pharmacy and two pharmaceutical companies began a collaborative pilot program to evaluate the potential contributions of clinically-trained pharmacists within a pharmaceutical industry practice setting. Following the successful pilot, the Rutgers Pharmaceutical Industry Fellowship (RPIF) Program grew significantly and expanded to include 21 companies within the pharmaceutical and biopharmaceutical industries and over 250 fellows annually.

In 2002, Dr. Ernest Mario generously provided an endowment to establish the Institute for Pharmaceutical Industry Fellowships to enhance and promote the role of pharmacists in industry through the RPIF Program. The Institute staff members:

- provide leadership and administrative support;
- promote quality, communication, and scholarly activity; and
- arrange specialized fellowship training opportunities within the pharmaceutical and biopharmaceutical industries.

Recently in 2018, our program has expanded to offer interdisciplinary fellows’ training by adding select physician fellowship opportunities to our well-established program.

The RPIF Program has thrived under the leadership of the founder, Dr. Joseph A. Barone, Dean and Professor II of the Ernest Mario School of Pharmacy and Dr. Lesley Fierro the Director for the Institute for Pharmaceutical Industry Fellowships.

More than 1000 post-doctoral fellows have completed the RPIF Program, most of whom are pursuing influential and rewarding careers in the pharmaceutical and biopharmaceutical industries throughout the US and abroad. The RPIF Program has preceptors/mentors from industry who share their knowledge and experiences with the fellows through an intense but closely guided training program. Assignments and projects are challenging, meaningful, and designed to enhance understanding of the pharmaceutical and biopharmaceutical industries and the fellow’s functional area.
The Rutgers Pharmaceutical Industry Fellowship Program FOSTERs the growth and development of future pharmaceutical and biopharmaceutical industry professionals through the following key program features:

**F** Family of Leading Companies—Partners include several of the top 21 global pharmaceutical and biopharmaceutical companies.

**O** Outstanding Alumni Track Record—Over 1000 alumni hold prominent positions at many leading companies.

**S** Strong Network—Over 250 fellows each year develop valuable, lasting connections with each other, alumni, preceptors and faculty.

**T** The Pathway to Industry—Since 1984, the Rutgers program has been nationally recognized, trusted, and proven as the pathway to industry for pharmacists.

**E** Enhanced Career Path—Increasingly challenging assignments build depth of experience and enhance the potential for an accelerated career path.

**R** Rigorous Academic Component—Rutgers affiliation provides academic and professional development opportunities.

Rutgers, The State University of New Jersey, with approximately 70,875 students in its three campuses, is one of the major state university systems in the United States. The New Jersey College of Pharmacy was founded in 1892 and was incorporated into the University in 1927. The Ernest Mario School of Pharmacy is part of Rutgers Biomedical and Health Sciences, the only state school of pharmacy in New Jersey, with approximately 1,300 students in its Doctor of Pharmacy program. The Rutgers Ernest Mario School of Pharmacy is located on the University’s main science and technology campus in Piscataway, New Jersey. Because of its close proximity to the nation’s leading pharmaceutical and biopharmaceutical companies, the Ernest Mario School of Pharmacy and the RPIF Program are uniquely capable of providing fellows with advanced training in the pharmaceutical and biopharmaceutical industries.

Fellows for the Rutgers Pharmaceutical Industry Fellowship Program are selected on a nationally competitive basis. Candidates must have completed a Doctor of Pharmacy degree from an ACPE accredited institution before July 1 of the fellowship term. Due to the ongoing pandemic, participation in PPS/ASHP is required. The PPS Portal will be necessary to request an interview with positions of interest. In addition, interested individuals may submit their application materials (curriculum vitae, three letters of recommendation and a letter of intent) beginning September 2020 by visiting our website at: pharmfellows.rutgers.edu

All application materials must be submitted electronically to the RPIF Website, in addition to requesting an interview via the PPS Portal.

**How To Apply:**

<table>
<thead>
<tr>
<th>Required Items</th>
<th>Deadline*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Curriculum Vitae (CV)</td>
<td>November 6th</td>
</tr>
<tr>
<td>Letter of Intent (LOI)</td>
<td>November 6th</td>
</tr>
<tr>
<td>Letters of Recommendation (LORs)</td>
<td>December 4th</td>
</tr>
</tbody>
</table>

*This is a rolling submission. Applicants are strongly encouraged to submit application materials as soon as possible to request an interview. The final day to request an interview via the PPS Portal is November 06, 2020 at 11:59 PM PST.

Please address your Letter of Intent & Letters of Recommendation to:
Joseph A. Barone, Pharm.D., F.C.C.P.
Dean and Professor II
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey
160 Frelinghuysen Road
Piscataway, NJ 08854-8020